A novel GIP receptor antagonist was developed to evaluate the acute role of glucose-dependent insulinotropic polypeptide (GIP) in the insulin response to oral glucose in rats. Antisera to an extracellular epitope of the GIP receptor (GIPR) detected immunoreactive GIPR on rat pancreatic ␤-cells. Purified GIPR antibody (GIPR Ab) specifically displaced GIP binding to the receptor and blocked GIPmediated increases in intracellular cAMP. When delivered to rats by ip injection, GIPR Ab had a half-life of approximately 4 days. Treatment with GIPR Ab (1 g/g BW) blocked the potentiation of glucosestimulated insulin secretion by GIP (60 pmol) but not glucagon-like peptide-1 (GLP-1, 60 pmol) in anesthetized rats. The insulin response to oral glucose was delayed in conscious unrestrained rats that were pretreated with GIPR Ab. Plasma insulin levels were ϳ35% lower at 10 min in GIPR Ab treated animals compared with controls. As a result, the glucose excursion was greater in the GIPR Ab treated group. Fasting plasma glucose levels were not altered by GIPR Ab. We conclude that release of GIP following oral glucose may act as an anticipatory signal to pancreatic ␤-cells to promote rapid release of insulin for glucose disposal. (Endocrinology 141: 3710 -3716, 2000) 
stimulated insulin secretion by GIP (60 pmol) but not glucagon-like peptide-1 (GLP-1, 60 pmol) in anesthetized rats. The insulin response to oral glucose was delayed in conscious unrestrained rats that were pretreated with GIPR Ab. Plasma insulin levels were ϳ35% lower at 10 min in GIPR Ab treated animals compared with controls. As a result, the glucose excursion was greater in the GIPR Ab treated group. Fasting plasma glucose levels were not altered by GIPR Ab. We conclude that release of GIP following oral glucose may act as an anticipatory signal to pancreatic ␤-cells to promote rapid release of insulin for glucose disposal. I T HAS BEEN recognized for decades that the secretory response of the endocrine pancreas is much greater after oral than after iv glucose (1) (2) (3) . During a meal, insulin secretion from pancreatic ␤-cells is potentiated by nutrient, neural, and hormonal signals arising from the gut-the socalled enteroinsular axis (4, 5) . The two major gut insulinotropic hormones, or incretins, are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) (6, 7) . There have been numerous studies aimed at determining the relative importance of GIP and GLP-1 in the enteroinsular axis. Dose-response analyses of the insulinotropic activity of these two incretin hormones indicate that lower concentrations of GLP-1 are required to augment insulin secretion, particularly at elevated glucose concentrations (8 -19) . However, while GLP-1 appears more potent than GIP, the rise in immunoreactive GIP levels following oral glucose is greater in magnitude than the increment in plasma immunoreactive GLP-1 after a similar load (14, 20 -27) . When infused at doses chosen to produce plasma levels roughly comparable to values measured after oral glucose in human subjects (ϳ450 pm and ϳ50 -60 pm, respectively) GIP appears to be more insulinotropic than GLP-1 (25) . Indeed, it has recently been suggested that the primary physiological role of GLP-1 may be inhibition of upper gastrointestinal motor and digestive functions rather then potentiation of meal-induced insulin secretion (28) .
Recently, both GLP-1 and GIP receptors have been disrupted in mice (29, 30) . Both models display glucose intolerance following oral glucose tolerance tests, firmly establishing the importance of both hormones in the maintenance of normal glucose homeostasis. However, it remains possible that the phenotype of these animals is modified in part by as of yet undetermined adaptive and developmental consequences to the chronic absence of incretin hormone action. For example, it has been recently reported that mice with a null mutation in the GLP-1 receptor have compensatory increases in GIP secretion and insulinotropic action (31) . Therefore, it is possible that the glucose intolerance in GIP knockout mice is attenuated by an adaptive increase in release and/or insulinotropic action of GLP-1. To determine the effect of an acute ablation of the insulinotropic action of GIP, we developed a novel specific GIP receptor antagonist. Here we characterize the antagonist and report on its acute actions on glucose tolerance in rats.
Materials and Methods

Generation and purification of GIP receptor antisera
Rabbits were immunized with a synthetic peptide of a specific epitope to the extracellular region of the rat GIP receptor (GQTTGELYQRW-ERYGWEC) coupled to maleimide activated keyhole limpet hemocyanin (Pierce Chemical Co., Rockford, IL). Antisera from one rabbit was purified by affinity chromatography. Antigen was coupled to ultralink immobilized diaminodipropylamine support using succinimidyl 4-(Nmaleimidomethyl) cyclohexane-1-carboxylate (Pierce Chemical Co.). Antisera was bound in 20 mm sodium phosphate buffer, pH 7.5, 500 mm NaCl and eluted in 0.1 m glycine⅐HCl, pH 2.8. Purified GIP receptor antibody (GIPR Ab) was then dialyzed in PBS, aliquoted and stored at Ϫ20 C.
GIP receptor expression
Pancreatic islets were isolated by a modification of the method described by Lacy and Kostianovsky (32) as previously described (33) 
GIPR Ab binding analysis
HEK 293 cells stably expressing either the GIP or GLP-1 receptor (generously provided by T. Usdin, National Institute of Mental Health, Bethesda, MD, and J. Gromada, Novo Nordisk A/S, University of Copenhagen, Denmark, respectively) were cultured in DMEM (Life Technologies, Inc., Grand Island, NY) containing 25 mm glucose supplemented with 100 U/ml penicillin, 100 g/ml streptomycin, and 10% FBS at 37 C in humidified 5% CO 2 -95% air. Cells were harvested for receptor binding studies with trypsin-EDTA, resuspended in binding buffer (138 mm NaCl, 5.6 mm KCl, 1.2 mm MgCl 2 , 2.6 mm CaCl 2 , 10 mm HEPES, 1% BSA, 10 mm glucose, and 1% aprotinin), and aliquoted into Eppendorf tubes (ϳ1 ϫ 10 6 cells/800 l). One hundred microliters of 125 I-GLP-1 7-36NH 2 or 125 I-GIP prepared as previously described (34) (ϳ30,000 cpm) and 100 l of affinity purified GIPR Ab (0.01-50 g/ml final concentration) was added to the appropriate tubes and the samples were rocked at room temperature for 30 min. Tubes were then centrifuged at 12,000 ϫ g for 5 min, and the cell pellet was counted in a ␥-counter. Results are expressed as a % of the maximum specific binding in the absence of GIPR Ab.
Measurements of intracellular cAMP were made on HEK 293 cells expressing the GIP receptor. Cells were plated into 24-well plates and cultured for 24 -48 h before assay. At the time of assay, cells were transferred into DMEM ϩ 0.1% BSA and incubated in triplicate with or without GIP (Peninsula Laboratories, Inc., Belmont, CA), GIP receptor antisera (1:100), or preimmune sera (1:100). After 5 min, cells were extracted in 0.5 ml ice-cold ethanol followed by freeze-thawing. Supernatants were then lyophilized, and cAMP quantity was determined by RIA using cAMP specific antisera (Biomedical Technologies, Inc., Stoughton, MA). The value for each well was determined in duplicate.
GIPR Ab kinetics
A sensitive ELISA was used to determine the half-life of GIPR Ab in vivo. The GIP receptor peptide fragment used as an antigen was coated at 1.0 g/ml on Falcon microtiter plates (Becton Dickinson and Co., Sparks, MD) in carbonate-bicarbonate buffer, pH 9.6. A standard curve was then constructed by incubating with a range of concentrations of GIPR Ab (0.0001 to 10 g/ml), followed by alkaline phosphatase conjugated antirabbit secondary antisera at 1:1000 (Jackson ImmunoResearch Laboratories, Inc.) and development in 1 mg/ml disodium pnitrophenyl phosphate substrate (Sigma-Aldrich Corp.) in 10% diethanolamine buffer, pH 9.8. Formation of p-nitrophenyl was monitored by absorbance at 405 nm.
Male Sprague Dawley rats (200 g) were given an ip injection of GIPR Ab (1 g/g BW) and tail vein blood samples were collected over the next 4 days. Plasma samples were diluted 1:10 and 1:100 and assayed by ELISA as described above. OD values were converted to concentration of GIPR Ab off the standard curve.
Glucose tolerance tests
Male Sprague Dawley rats (250 -300 g) (Biological Sciences Animal Services, University of Alberta, Edmonton, Alberta, Canada) received either 1.0 g/g BW GIPR Ab or 1.0 g/g BW rabbit ␥-globulin in PBS (Jackson ImmunoResearch Laboratories, Inc.) by ip injection, approximately 21 h before glucose tolerance testing. All studies were performed following an overnight fast. For iv glucose tolerance tests, rats were anesthetized by ip injection of 50 mg/kg BW sodium pentobarbital (Somnotol; MTC Pharmaceuticals, Cambridge, Ontario, Canada) and the right jugular vein was cannulated with PE 90 polyethlylene tubing (Becton Dickinson and Co.) for infusions. Experiments were performed 20 -30 min after implantation of the infusion catheter. Body temperature was maintained throughout experiments by use of heating pads. Rats were infused with either glucose alone (2.8 mmol/kg), glucose plus 60 pmol porcine GIP (American Peptide Co., Sunnyvale, CA), or glucose plus 60 pmol GLP-1 7-36NH 2 (Peninsula Laboratories, Inc.). Blood samples were collected from the tail vein into heparinized capillary tubes at time 0 and at 5, 10, 20, 30, and 60 min following infusions. The samples were immediately transferred into microcentrifuge tubes on ice, centrifuged at 12,000 ϫ g (4 C) for 5 min and the plasma was then stored at Ϫ20 C until assays were performed.
For oral glucose tolerance tests conscious, unrestrained rats that had received either GIPR Ab or control rabbit IgG injections were allowed to acclimate under a heat lamp for 20 to 30 min before the experiments. Glucose (1 g/kg BW) was administered orally as a 50% solution by gavage. Blood samples were collected at time 0 and at 10, 20, 30, 60, 90, and 120 min following oral glucose and were prepared as above for assays.
Assays
Plasma glucose was determined using a colorimetric enzymatic assay kit (Sigma, St. Louis, MO) scaled down for use in 96-well microtiter plates. Plasma insulin concentrations were measured with a RIA kit (rat insulin RIA kit, Linco Research, Inc., St. Charles, MO).
Data analysis
For the iv glucose tolerance test experiments, incremental area under the curve (AUC) was calculated using the trapezoidal rule from 5-30 min after the glucose infusion. This calculation is the sum of the products of the mean plasma glucose concentrations for each time period multiplied by the number of minutes in each time period, minus the product of the basal plasma glucose concentration multiplied by the total number of minutes. All values are presented as means Ϯ sem. Unpaired Student's t tests were used to identify differences between treatment groups.
Results
GIP receptor expression
The specificity of the antisera for the GIP receptor was first examined by Western blot analysis. A single product with an apparent molecular weight of 70K was detected in a total cell extract from HEK 293 cells overexpressing the GIP receptor (Fig. 1) . In contrast, no product was detected in an extract prepared from HEK 293 cells overexpressing the highly homologous GLP-1 receptor. In a total cell extract from rat islets a major product was detected with an apparent molecular weight of 65K (Fig. 1) . The difference in product size between the extracts may reflect different posttranslational processing of the GIP receptor.
The distribution of GIP receptors in rat pancreatic islets was determined by immunofluorescence techniques. GIP receptor immunoreactivity was detected throughout islets (Fig. 2) . In contrast, no specific immunoreactivity was detected with the preimmune sera.
GIPR Ab binding analysis
The affinity of the antibody for the GIP receptor was determined by 125 I-GIP binding analysis. Affinity purified GIPR Ab competitively displaced 125 I-GIP binding to cells stably transfected with the GIP receptor (Fig. 3) . Halfmaximal displacement was achieved with approximately 1 g/ml. No significant displacement of 125 I-GLP-1 nor 125 Iglucagon binding to INS-1 cells was observed (data not shown).
GIP induces concentration-dependent increases in cAMP production in GIP receptor expressing cells (35) . GIPR Ab alone had no effect on cAMP production in these cells, but the cAMP response to 0.1 nm GIP was reduced to a level not significantly different from basal (Fig. 4) .
GIPR Ab kinetics
Circulating levels of GIPR Ab were followed by a sensitive, specific ELISA in plasma samples from rats following ip injection (1 g/g BW). Plasma levels peaked at approximately 20 g/ml after 4 h, remained at this level for 2 days, and were half-maximal after 4 days (Fig. 5) .
Glucose tolerance tests
The ability of the GIPR Ab to block the insulinotropic action of exogenous GIP in vivo was examined in anesthetized rats. In animals receiving iv glucose, administration of GIPR Ab had no effect when compared with IgG-treated animals on glucose area under the curve (AUC; 263 Ϯ 11 vs. 271 Ϯ 8 mm ϫ min) or peak plasma insulin concentrations (751 Ϯ 57 vs. 854 Ϯ 157 pm) (Fig. 6 ). Coinfusion of a 60 pmol bolus of GIP increased peak insulin levels by approximately 2-fold and reduced the glucose AUC by approximately 15% in control animals receiving IgG. In the animals treated with GIPR Ab, this insulinotropic effect of GIP was completely ameliorated (864 Ϯ 83 vs. 1521 Ϯ 161 pm; P Ͻ 0.01) and the AUC was significantly greater than in the IgG-treated group (271 Ϯ 14 vs. 233 Ϯ 9 mm ϫ min; P Ͻ 0.05). In control animals receiving IgG, coinfusion of a 60 pmol bolus of GLP-1 increased peak insulin levels nearly 3-fold and reduced the glucose AUC by approximately 15%. Treatment with GIPR Ab had no significant effect on the insulinotropic action of GLP-1 (1864 Ϯ 500 vs. 2488 Ϯ 321 pm) or glucose AUC (241 Ϯ 7 vs. 228 Ϯ 14 mm ϫ min).
The effect of acute blockage of GIP action on oral glucose tolerance was examined in conscious unrestrained rats. Basal fasting glucose levels were not different between control rats and those that received GIPR Ab. During the oral glucose tolerance test, the insulin response was delayed in rats pretreated with GIPR Ab compared with controls pretreated with rabbit IgG (Fig. 7) . Insulin levels 10 min after oral glucose were reduced by approximately 35% by GIPR Ab (245 Ϯ 29 vs. 355 Ϯ 42 pm; P Ͻ 0.05). This was accompanied by an increase in the glucose excursion compared with the IgGtreated control group. In controls, glucose levels declined after the 20 min sampling point. In contrast, glucose levels remained elevated in GIP receptor antibody treated animals until the 30 min sampling point (12.9 Ϯ 0.5 vs. 11.4 Ϯ 0.3 mm; P Ͻ 0.05).
Discussion
Previous attempts have been made to acutely disrupt GIP action in vivo to assess its contribution to the enteroinsular axis. Early studies used antisera raised to GIP preparations purified from gut extracts (36 -39) . In these studies, it was estimated that anywhere from 50 -100% of the incretin effect was blocked by the anti-GIP sera, suggesting GIP to be the major incretin hormone. However, the gut extracts used to generate the antisera were as little as 40% pure (37), and therefore the resulting polyclonal antisera may have neutralized additional gut hormones. More recently, peptide antagonists of both GIP and GLP-1 have been used to acutely examine incretin hormone action. Both the GIP fragment 7-30 and the exendin fragment 9 -39 disrupt the insulin response to oral nutrients in rodents (35, 40 -42) . However, limitations of these peptide antagonists for in vivo work include the short half-life (minutes), the nonspecificity at high doses (43, 44) , and the possibility that degradation products may have additional unknown biological properties. Therefore, we used an alternative approach to develop a specific, long-lasting antagonist of GIP to re-evaluate its acute role in oral glucose tolerance.
Antiserum was generated to a specific epitope in the ex- tracellular region of the rat GIP receptor. In extracts from rat pancreatic islets, this antiserum detected a product of the approximate size predicted for the GIP receptor. GIP receptor immunoreactivity was located throughout islets, including both ␤-and ␣-cells, as expected from previous reports which identified both messenger RNA and binding sites on these cell types (45, 46) . These findings support the concept that the insulinotropic and glucagonotropic actions of GIP (47) are mediated through direct actions of GIP on ␤-and ␣-cells, respectively. Purified GIP receptor antibody (GIPR Ab) bound to the GIP receptor with high affinity and thereby prevented GIP from activating the receptor, both in vitro and in vivo. Notably, GIPR Ab did not bind to the related receptors for GLP-1 and glucagon. This GIP receptor antagonist was remarkably stable in vivo, with half-maximal levels following a single ip injection remaining after 4 days. Pretreatment of rats with GIPR Ab significantly attenuated the insulin response to oral glucose resulting in a greater glucose excursion. These findings confirm the importance of GIP in the rapid ␤-cell response to glucose. However, the rather modest effect of acute ablation of the GIP signal illustrates the remarkable redundancy of the enteroinsular axis. For example, the autonomic nervous system has recently been shown to play a crucial role in glucose-and meal-induced insulin release (48, 49) . Glucose itself is also a potent insulin secretagogue. Thus, with these additional pathways remaining intact following blockage of GIP action, sufficient insulin was still released from ␤-cells to adequately absorb the glucose challenge, albeit with suboptimal kinetics. It is also possible that delayed glucose absorption from the gut in rats pretreated with GIPR Ab reduced the severity of the glucose intolerance following disruption of the insulinotropic activity of GIP. GIP, but not GLP-1, increases jejunal basolateral glucose transport activity (50, 51) . Consistent with these findings, treatment with a GIP peptide antagonist reduced absorption of glucose from the small intestine of rats (40) .
The effect of acute GIP antagonism was not as marked as was observed in GIP receptor knockout mice (30) . Mice with disrupted expression of the GIP receptor exhibit severe glucose intolerance. Peak plasma glucose values were approximately 30% higher than control mice following an oral glucose challenge (compared with 13% in our study). This apparent difference in findings may be explained by the fact that Miyawaki et al. (30) used a glucose challenge that was double the dose we used in this study, thereby perhaps making the result of absent GIP signaling more evident. Significant differences are beginning to emerge between the roles of GIP and GLP-1 in the maintenance of normal glucose homeostasis. Neither acute nor chronic impairment of GIP action seems to alter fasting plasma glucose levels, as expected for a hormone acting in the classical incretin fashion. In contrast, glucose intolerance in mice with a disrupted GLP-1 receptor is frequently accompanied by fasting hyperglycemia (29) . Perhaps even more surprising is the observation that mice with a null mutation in the GLP-1 receptor also exhibit abnormally elevated levels of blood glucose following ip glucose challenge where glucose bypasses the enteroinsular axis entirely (29) . This observation was not made in mice with a disrupted GIP receptor (30) . When compared with control mice, disrupted incretin hormone action would not be expected to impair clearance of a glucose challenge that bypasses the gut as both GIP and GLP-1 are released in response to luminal, but not iv, glucose (9, 27, 52, 53). Therefore, while GIP appears to act as an acute insulinotropic hormone in order that ␤-cells may anticipate the absorption of glucose from the gut, GLP-1 signaling appears to be additionally important for the maintenance of normoglycemia, irrespective of the site of glucose entry into the circulation. This ability to promote glucose disposal makes GLP-1 a candidate therapeutic for the treatment of the abnormal glucose homeostasis associated with diabetes mellitus (7) .
In summary, GIP receptors are present on rat pancreatic ␤-cells where GIP is insulinotropic. Acute disruption of GIP action has no effect on fasting glucose levels but delays the insulin response to oral glucose and thereby increases the plasma glucose excursion. Therefore, GIP release from the upper intestine in response to the ingestion of nutrients (e.g. glucose) may act as an anticipatory signal to the ␤-cells to ensure insulin is rapidly released as glucose is absorbed from the gut.
